Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01512251 · ClinicalTrials.gov registry record · Phase 1
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01512251 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 8 participants.
The verdict
NCT01512251, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a phase 1/2 clinical trial with the goal of determining whether the addition of the investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free survival in patients with BRAFV600E/K mutant melanoma.
Interventions
- DRUG BKM120 Combined with Vemurafenib (PLX4032)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-06-09 |
| Est. Completion | 2017-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01512251
The ClinicalTrials.gov registry entry for NCT01512251 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BKM120 Combined with Vemurafenib (PLX4032) is the first listed.
NCT01512251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01512251 about?
NCT01512251 is a clinical study titled "BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma". This is a phase 1/2 clinical trial with the goal of determining whether the addition of the investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free survival in patients with BRAFV600E/K mutant melanoma.
What is the current status of trial NCT01512251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2012-06-09. Estimated completion is 2017-03-21.
What interventions are being tested in trial NCT01512251?
The interventions under investigation include: BKM120 Combined with Vemurafenib (PLX4032) (DRUG).
Who is sponsoring clinical trial NCT01512251?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.